Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $331,711.38 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 11,466 shares of the stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $28.93, for a total transaction of $331,711.38. Following the completion of the transaction, the chief operating officer directly owned 377,802 shares of the company’s stock, valued at $10,929,811.86. This trade represents a 2.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

  • On Thursday, November 12th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $29.40, for a total transaction of $349,301.40.
  • On Monday, November 9th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $30.12, for a total transaction of $357,855.72.
  • On Thursday, November 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.53, for a total transaction of $315,202.93.
  • On Friday, October 30th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.73, for a total transaction of $317,579.13.
  • On Monday, November 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.47, for a total transaction of $302,609.07.
  • On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.45, for a total transaction of $338,014.45.
  • On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.04, for a total transaction of $309,381.24.
  • On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.98, for a total transaction of $296,787.38.
  • On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.05, for a total transaction of $285,738.05.
  • On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.41, for a total transaction of $301,896.21.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ:ADPT opened at $29.04 on Monday. The company has a fifty day moving average of $26.91 and a 200-day moving average of $20.13. The company has a market capitalization of $4.70 billion, a PE ratio of -64.53 and a beta of 2.18. The company has a debt-to-equity ratio of 1.82, a quick ratio of 3.87 and a current ratio of 3.97. Adaptive Biotechnologies Corporation has a 52-week low of $12.00 and a 52-week high of $32.21.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.12. Adaptive Biotechnologies had a negative return on equity of 23.95% and a negative net margin of 23.67%. The company had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $71.57 million. During the same period in the prior year, the company earned $0.06 EPS. Adaptive Biotechnologies’s revenue was down 10.7% compared to the same quarter last year. On average, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wasatch Advisors LP bought a new position in Adaptive Biotechnologies during the 2nd quarter worth $12,361,000. Renaissance Technologies LLC acquired a new position in Adaptive Biotechnologies during the 1st quarter worth about $3,328,000. Handelsbanken Fonder AB bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter valued at about $1,416,000. Wellington Management Group LLP grew its position in shares of Adaptive Biotechnologies by 53.2% in the 2nd quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock valued at $126,799,000 after buying an additional 2,053,944 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter valued at about $9,207,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ADPT shares. Guggenheim upped their target price on Adaptive Biotechnologies from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. TD Cowen increased their target price on Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Morgan Stanley lifted their price target on Adaptive Biotechnologies from $22.00 to $27.00 and gave the company an “equal weight” rating in a research note on Monday, October 12th. National Bank Financial set a $34.00 price target on Adaptive Biotechnologies in a research note on Tuesday, September 22nd. Finally, BTIG Research boosted their price target on Adaptive Biotechnologies from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Tuesday, September 22nd. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average target price of $30.31.

Check Out Our Latest Report on Adaptive Biotechnologies

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies is a biotechnology company focused on using the human immune system to diagnose and treat disease. Based in Seattle, Washington, the company develops technologies that sequence and analyze immune cells and their receptors, generating data for clinical testing, research and drug development. Its products include immunoSEQ, a platform used by researchers and biopharmaceutical companies to study immune responses, and clonoSEQ, a clinical test that detects and monitors minimal residual disease in certain blood cancers.

Recommended Stories

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.